Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

June 30, 2024

Conditions
Hepatitis C
Interventions
DEVICE

OraQuick HCV Antibody test (OraSure Technologies, Inc)

The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.

DEVICE

Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)

Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.

DRUG

Sofosbuvir/Velpatasvir (Gilead)

Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.

Trial Locations (6)

3066

RECRUITING

Innerspace, Collingwood

3168

RECRUITING

Mediclinic Australia, Clayton South

3214

RECRUITING

Corio Community Health Centre, Corio

6003

RECRUITING

Homeless Healthcare, Highgate

6164

RECRUITING

Cockburn Wellbeing, Success

3065.

RECRUITING

Cohealth Fitzroy, Fitzroy

All Listed Sponsors
lead

Macfarlane Burnet Institute for Medical Research and Public Health Ltd

OTHER